Benchmark
Official requirements
The twelve project numbers and names follow Ministry of Health and Welfare Notice 2025-961, announced on 31 December 2025 for the first new awards of 2026. This screen sets what the call asks beside the programme’s internal target.
The internal targets come from the programme’s own research specification. Meeting one is a separate matter from meeting the call. The programme does not claim support, selection or recognised outcomes under the call.
Twelve projects against the source text
Page numbers are those printed in the proposal requirements. The column lists the items a single auditor most needs to tell apart; eligibility, special conditions and outcome targets are on the same pages.
| Project | Internal research target | What the call asks, in part | Pages |
|---|---|---|---|
| 5-1 · AI drug discovery | Binding free-energy error of 1 kcal/mol or less | Led by a company that holds an AI drug-discovery platform, with a pharmaceutical or biotech partner. Outcomes include the platform and its efficacy results, a candidate ready for non-clinical entry with safety and efficacy test reports, and a substance patent filing. | 18–20 |
| 8-1 · Synthetic data | At least 95% of downstream predictive performance retained | Open to existing or ongoing national health R&D projects at TRL 3 or above. Stage one supports commercialisation strategy and consulting; stage two supports competitive follow-on development. | 31–36 |
| 18-2 · Medication safety | Zero missed contraindications or look-alike medication errors | Infusion over-rate and dispensing errors are separate support areas. Validation at three or more hospitals is required, and stage-two outcomes for the over-rate area include regulatory approval. | 97–100 |
| 19-1 · Rare disease diagnosis | At least 90% of causal genes in the top five | At least one clinician must be a principal or co-principal investigator. Papers, patents and stage-by-stage practical-use materials are required, and a disease indicator needs sensitivity and specificity data. | 105–107 |
| 16-2 · Adaptive cognitive training | Difficulty convergence in at least 95% of simulated episodes | Requires company participation, demonstrated clinical efficacy, approval of a confirmatory clinical trial plan and papers. | 79–81 |
| 16-3 · Dementia diagnosis | External cohort AUROC of at least 0.90 | Prediction and diagnosis areas require a completed exploratory clinical performance study or an approved confirmatory study plan. The imaging area requires validation at two or more independent tertiary hospitals. Both areas set paper targets. | 82–84 |
| 18-1 · Fall early warning | At least 92% early-warning sensitivity in the high-risk group | Clinical efficacy and field acceptance are evaluated through multi-site clinical validation, with field measures such as fall incidence, work efficiency and alarm fatigue. | 94–96 |
| 18-3 · Surgical safety | Zero instrument count omissions on the fixed test | Automatic counting of surgical instruments and patient identification before and after surgery are separate areas. Validation takes place in real operating rooms at three or more hospitals, with designated types of institution taking part. | 101–104 |
| 12-1 · Acute crisis signals | At least 90% recall for acute crisis signals | Covers community programme development and field validation in urban, rural and alcohol-use-disorder areas. The urban area specifies at least 400 participants and four or more institutions. | 53–56 |
| 12-2 · Safety-plan transitions | Zero clinically disallowed response events on the fixed test | Bereaved families and people who have survived an attempt are separate areas, with field validation of at least 100 and 200 participants respectively and four or more institutions in each. | 57–59 |
| 12-3 · Social isolation | At least 85% precision for detecting transitions into sustained isolation | Field validation with community partner organisations, with at least 100 participants at four or more sites, followed by analysis of satisfaction and effect. | 60–62 |
| 12-4 · Student crisis handoffs | 100% immediate handoff after a detected crisis state | School-based crisis intervention and student prevention programmes form a separate area, with outcomes set per area, including validation in schools and communities, training and papers. | 63–66 |
What this comparison covers
The check covered the text of the call, the relevant pages of the proposal requirements and the data providers’ access notices. Acquiring row-level data, training models, applying to the call and being selected are outside it.